Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.
Shingrix (Zostavax) Market Forecast: What Value Will The Market Reach By 2030?
During the historical period, the observed growth was due to several factors including a greater understanding of shingles complications, the expansion of the global aging population, the earlier limitations of live attenuated vaccines, the broadening of immunization guidelines for older individuals, and a rise in the rates of physician recommendations.
Factors contributing to the projected growth include more ambitious adult vaccination coverage targets, increased healthcare expenditure on preventive care, the broadening of recombinant vaccine development pipelines, a rise in government-backed immunization initiatives, and a heightened focus on alleviating the burden of post-herpetic neuralgia.
Key trends anticipated over the forecast timeframe involve the wider adoption of recombinant vaccine technologies, a stronger emphasis on adult immunization programs, an increasing demand for long-lasting protection against shingles, the expansion of cold-chain optimized vaccine distribution networks, and a heightened importance placed on vaccine safety and efficacy.
Get A Free Sample Report With In-Depth Market Insights:
Shingrix (Zostavax) Market Growth Drivers: What’s Behind The Acceleration?
The expanding uptake of vaccination is anticipated to propel the shingrix (zostavax) market forward. Vaccination involves giving a vaccine to prompt the body’s immune system to identify and combat specific disease-causing agents. This rise in vaccination adoption stems from greater understanding of its efficacy in preventing illnesses, decreasing disease impact, and the availability of secure and accessible vaccines. Furthermore, public health efforts, better healthcare infrastructure, and worldwide vaccination programs contribute to its widespread acceptance. Shingrix (Zostavax) offers advantages for vaccination by providing robust defense against shingles and its associated issues. It is particularly valuable for adults aged over 50, substantially lowering the chance of shingles reappearance and post-herpetic neuralgia. For example, in May 2024, a study published by the Journal of the American Medical Association (JAMA), a US-based medical journal, indicated that shingles vaccinations covered by Medicare Part D saw a 46% increase in the year following the IRA policy’s implementation in January 2023. Consequently, the increasing adoption of vaccination is driving the expansion of the shingrix (zostavax) market.
Shingrix (Zostavax) Market Segment Analysis And Revenue Potential
The shingrix (zostavax) market covered in this report is segmented –
1) By Formulation: Recombinant Vaccine (Shingrix), Live Attenuated Vaccine (Zostavax)
2) By Indication: Shingles Prevention, Post-Herpetic Neuralgia
3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy
Shingrix (Zostavax) Market Trends: What’s Defining The Industry’s Next Phase?
Major companies in the shingrix (zostavax) market are focused on developing innovative solutions, such as non-live, recombinant subunit adjuvanted vaccines, to fulfill the increasing demand for safer and more effective immunization, primarily driven by age-related immune decline and the necessity for options suitable for immunocompromised populations. A non-live, recombinant subunit adjuvanted vaccine incorporates specific protein components (antigens) from a pathogen, combined with an adjuvant to enhance the immune response, contrasting with traditional live-attenuated vaccines that utilize weakened forms of the entire virus. For example, in 2023, GSK plc, a biopharmaceutical company headquartered in the UK, launched Shingrix (Recombinant Zoster Vaccine, RZV) in India. This vaccine is non-live, administered intramuscularly in two doses, and contains the glycoprotein E antigen in conjunction with GSK’s proprietary AS01B adjuvant system. Shingrix elicits a strong and durable immune response, effectively countering the decrease in immunity among older adults, and provides very high efficacy (up to ~97%).
Shingrix (Zostavax) Market Key Players Shaping Industry Direction
Major companies operating in the shingrix (zostavax) market are GSK plc
View The Full Shingrix (Zostavax) Market Report:
Shingrix (Zostavax) Market Regional Breakdown: Where Is Demand Concentrated?
North America was the largest region in the shingrix (zostavax) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the shingrix (zostavax) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
